Omental Endothelial Cells Drive Ovarian Cancer Growth: New Study Challenges the Adipocyte Theory

For years, researchers studying ovarian cancer spread through the abdomen have focused heavily on one feature of the omentum: its fat cells. Now, new research suggests that assumption may be incomplete.

A study published in Nature Communications has found that mature adipocytes are not required for peritoneal ovarian cancer expansion. Instead, the blood-vessel lining cells of the omentum, known as endothelial cells, emerged as a potentially important component of the tumour-supporting environment.

The findings could change how scientists think about ovarian cancer metastasis. Rather than viewing the omentum simply as a fatty organ that supplies cancer cells with energy-rich lipids, the research points toward a more complicated biological ecosystem in which blood vessels and their lipid-handling machinery may help create conditions favourable to tumour growth.

Researchers led by Minz and colleagues at Washington University in the United States used multiple experimental ovarian cancer models and genetically modified mice to separate the effects of mature adipocytes from other components of the omental environment. Their experiments showed that ovarian tumours continued to preferentially colonise adipose-associated regions even when mature adipocytes were absent.

Yet removing the adipocyte-free omentum itself substantially reduced tumour burden. That apparent contradiction provided the central clue: something other than mature fat cells within the omental niche was helping the cancer grow.

Why the omentum matters in ovarian cancer

The omentum is a sheet-like fold of tissue containing fat, blood vessels, immune cells and connective tissue that lies within the abdominal cavity. It has an important physiological role, but it can also become a favoured destination for metastatic ovarian cancer.

Ovarian cancer frequently spreads across the peritoneal cavity. Cancer cells can detach from the primary tumour, travel through abdominal fluid and establish deposits on surfaces within the abdomen.

The omentum is particularly important in this process.

Once cancer cells reach the omentum, they interact with the surrounding cells and extracellular environment. This interaction is often described as the tumour microenvironment—the network of non-cancerous cells, blood vessels, signalling molecules and structural components that can either restrain or support tumour growth.

Understanding this environment is critical because metastatic cancer is not simply a collection of malignant cells growing independently. Tumour cells can effectively reshape nearby tissue to obtain nutrients, evade immune attack and build a blood supply.

The old assumption: ovarian cancer needs mature fat cells

Because the omentum is rich in adipose tissue, researchers have long been interested in the role of adipocytes, the mature cells responsible for storing fat.

Previous research suggested that ovarian cancer cells can interact with adipocytes and obtain fatty acids from the surrounding tissue. These lipids can potentially be used to support energy metabolism and other cellular processes required for rapid growth.

This led to a relatively straightforward model: the fatty omentum feeds ovarian cancer.

But the new study asks a more fundamental question: are mature adipocytes actually necessary for ovarian cancer to establish and expand within the peritoneal cavity?

The researchers designed their experiments specifically to answer that question rather than simply observing whether fat cells and cancer cells are found together.

What happened when mature adipocytes were removed?

The researchers used mice that congenitally lacked mature adipocytes within the peritoneal cavity, including the omentum. This created an unusual experimental environment in which ovarian cancer cells could encounter an omental region without the mature fat cells normally present there.

Several ovarian cancer models were tested, including ID8p53−/−Brca2−/−, BPPNM and KPCA.

If mature adipocytes were essential for ovarian cancer growth, removing them should have dramatically reduced tumour development.

That is not what happened.

The tumours continued to preferentially seed adipose-associated regions, even though mature adipocytes were missing. More importantly, the absence of mature adipocytes did not prevent overall peritoneal tumour expansion.

This was the first major clue that the relationship between ovarian cancer and the omentum was more complicated than a simple cancer-cell-to-fat-cell interaction.

The omentum still mattered—even without fat cells

The next observation was even more revealing.

When the researchers removed the adipocyte-free omentum, tumour burden fell substantially.

In other words, mature adipocytes were not necessary, but the omental environment itself remained important.

This distinction changes the question from “How do fat cells feed ovarian cancer?” to “Which other cells in the omentum create a tumour-supportive environment?”

The researchers turned to single-cell transcriptomic analysis to investigate the cellular composition and gene activity of the omental niche.

Endothelial cells emerge as the unexpected suspect

Blood vessels are not merely pipes that deliver oxygen and nutrients. The cells lining those vessels, called endothelial cells, actively communicate with surrounding tissues and can influence inflammation, metabolism, tissue repair and tumour biology.

The single-cell analysis revealed that FABP4 and other lipid-handling genes were enriched in omental endothelial cells.

FABP4, or fatty acid-binding protein 4, is commonly associated with lipid metabolism and adipose biology. Its presence in omental endothelial cells therefore offered a potentially important connection between the earlier adipocyte-focused research and the new findings.

The implication is subtle but significant: some of the lipid-handling functions previously attributed mainly to adipocytes may also be performed or regulated by endothelial cells within the omental microenvironment.

That could help explain why ovarian cancer continued to favour the omentum despite the absence of mature fat cells.

What is FABP4?

Fatty acid-binding protein 4, or FABP4, is a protein involved in the handling and transport of fatty acids within cells. It has been extensively studied in adipose tissue and metabolic biology.

In Cancer Research, lipid metabolism has become an increasingly important area of investigation. Tumour cells require substantial amounts of energy and cellular building blocks, and cancer can alter the way surrounding tissues store, release and process nutrients.

The new research places FABP4 in an unexpected location: endothelial cells within the omental environment.

That does not mean FABP4 is itself a proven human ovarian cancer drug target. Instead, it provides a mechanistic clue that researchers can investigate further.

Deleting endothelial FABP4 reduced tumour growth

The researchers next tested whether FABP4 within endothelial cells was merely a marker of the omental environment or whether it actually contributed to tumour progression.

They used an endothelial-specific genetic deletion of FABP4.

The result was notable: endothelial FABP4 deletion reduced omental tumour expansion and limited tumour vascular complexity.

This finding strengthens the argument that endothelial cells are not simply passive bystanders surrounding the tumour. Their metabolic characteristics may influence the tumour-supportive properties of the omental niche.

It also creates a possible link between metabolism and angiogenesis.

Why blood-vessel complexity matters

Growing tumours require access to oxygen and nutrients. To sustain expansion, they can stimulate the formation and remodelling of blood vessels through a process known as angiogenesis.

But tumour-associated blood vessels are often abnormal. They can become highly branched, irregular and inefficient, creating a complicated vascular environment that nevertheless helps support tumour survival.

The finding that endothelial FABP4 deletion reduced vascular complexity suggests that FABP4 may influence how the omental vascular network responds to ovarian cancer.

This raises an important possibility: the protein could be involved not simply in supplying tumour cells with lipids, but in shaping the vascular environment in which metastatic cancer grows.

A new model of ovarian cancer growth in the omentum

The study supports a more sophisticated model of what happens when ovarian cancer reaches the omentum.

This shift is important because it broadens the definition of the ovarian cancer microenvironment. The disease may exploit an entire cellular network rather than relying on a single neighbouring cell type.

Why the finding matters for ovarian cancer research

Ovarian cancer is often diagnosed after it has already spread within the abdominal cavity. That makes metastatic biology particularly important.

If scientists can identify why certain abdominal tissues are more welcoming to metastatic cancer cells, they may eventually be able to interfere with the process before widespread tumour growth becomes established.

The new study suggests that the omental microenvironment could be an active participant in this process.

That opens several research questions:

• How does endothelial FABP4 alter the behaviour of ovarian cancer cells?
• Does FABP4 directly influence lipid availability within the tumour microenvironment?
• How does endothelial FABP4 affect angiogenesis and vascular organisation?
• Do the same mechanisms operate in human ovarian cancer tissues?
• Could blocking this pathway enhance existing ovarian cancer treatments?
• Could endothelial metabolic signatures help predict which tumours are more likely to colonise the omentum?

The study also challenges how cancer metabolism is understood

One of the most interesting aspects of the research extends beyond ovarian cancer.

Cancer metabolism is often discussed as though tumour cells alone control their metabolic needs. Increasingly, researchers are finding that cancer cells can manipulate surrounding tissues to obtain nutrients and create favourable metabolic conditions.

The omental findings fit this broader concept.

If endothelial cells can perform important lipid-handling functions within a metastatic niche, then metabolic support for cancer may come from unexpected cellular sources.

This could be especially important in metastatic disease, where cancer cells enter tissues with very different metabolic environments from the original tumour.

Could FABP4 become a future treatment target?

It is tempting to jump from a genetic experiment to a new cancer treatment. The evidence does not yet support that conclusion.

The study shows that deleting endothelial FABP4 in experimental models reduced tumour growth and vascular complexity. That establishes a potential biological role, but it does not demonstrate that a FABP4-targeting drug would be safe or effective in people with ovarian cancer.

Endothelial cells perform essential functions throughout the body. A treatment that interferes with a protein involved in lipid metabolism could have effects beyond the tumour microenvironment.

Researchers would therefore need to determine whether the cancer-supporting activity of FABP4 can be selectively disrupted without causing unacceptable effects in healthy tissues.

The next stage is likely to involve more detailed molecular studies, human tissue validation and eventually therapeutic experiments.

What this means for patients today

For patients with ovarian cancer, the findings are important scientifically but do not currently change standard treatment.

The study does not establish a new approved therapy, screening test or dietary recommendation. Patients should not attempt to alter fat intake or use unproven FABP4-targeting supplements or medications based on these findings.

Instead, the immediate value is in improving researchers’ understanding of why ovarian cancer spreads to the omentum and which non-cancerous cells may help it thrive there.

That knowledge could eventually contribute to therapies designed to attack the tumour and its supporting environment simultaneously.

Why animal-model findings need careful interpretation

The study used sophisticated mouse models, including models that lacked mature adipocytes and others representing different ovarian cancer genetic backgrounds. This provides valuable experimental control that would be impossible to achieve directly in humans.

However, mouse biology does not perfectly reproduce human cancer biology.

The human omentum contains a complex mixture of adipocytes, endothelial cells, immune cells, fibroblasts and other cell types. Tumours developing in people also evolve over longer periods and are exposed to different immune, hormonal and metabolic conditions.

The researchers’ use of human and murine single-cell transcriptomic data strengthens the relevance of the findings, but additional work is still required before the mechanism can be considered a clinically validated target.

The bigger picture: cancer is an ecosystem

The most important conceptual takeaway from this research may be that ovarian cancer does not grow in isolation.

A metastatic tumour is an ecosystem. Cancer cells interact with blood vessels, immune cells, connective tissue and metabolic pathways. These interactions can determine whether a cancer cell dies, remains dormant or develops into an expanding tumour deposit.

The omentum appears to be particularly effective at creating a supportive environment for ovarian cancer. The new study suggests that its ability to do so cannot be explained simply by the presence of mature fat cells.

That is a valuable correction to an overly simple model.

Instead of asking only what cancer cells consume, researchers may increasingly need to ask which neighbouring cells make those resources available and how those cells are reprogrammed by cancer.

What could happen next?

The research creates a potential roadmap for future investigation.

• Researchers can map endothelial FABP4 signalling in greater detail.
• Human ovarian cancer samples can be examined to determine whether the same endothelial signature is present.
• Scientists can investigate whether FABP4 influences tumour metabolism, angiogenesis or both.
• Drug-development studies can test whether endothelial FABP4 can be safely inhibited.
• Future studies can determine whether targeting the endothelial niche works better when combined with existing anticancer treatments.

One particularly interesting possibility is that treatment may eventually target both the cancer cell and the tissue environment that enables metastatic growth.

Conclusion: the fat cell may not be the main culprit

The new research provides an important rethink of how ovarian cancer interacts with the omentum.

Although the omentum is rich in adipose tissue and mature adipocytes have traditionally been viewed as important sources of metabolic support, the experiments showed that ovarian cancer could continue to expand without mature adipocytes.

At the same time, removing the omentum itself reduced tumour burden, indicating that other components of this tissue were still supporting cancer growth.

Omental endothelial cells—and particularly their expression of FABP4—emerged as a compelling candidate. Removing FABP4 specifically from endothelial cells reduced tumour expansion and vascular complexity in the experimental models.

The finding does not yet translate into a new treatment for patients. But it changes the research question in an important way. The future of ovarian cancer therapy may depend not only on killing tumour cells, but also on disrupting the specialised environments that help those cells survive and spread.

For a cancer in which peritoneal dissemination remains a major clinical challenge, understanding why the omentum welcomes metastatic cells could ultimately be as important as understanding the cancer cells themselves.